Nephros, Inc.
NEPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.10 | -0.80 | 0.14 | 0.12 |
| FCF Yield | 0.20% | 2.29% | 1.77% | 8.41% |
| EV / EBITDA | 125.48 | 140.15 | 25.58 | 32.88 |
| Quality | ||||
| ROIC | 2.84% | 2.20% | 5.33% | 3.04% |
| Gross Margin | 61.19% | 63.25% | 64.67% | 63.95% |
| Cash Conversion Ratio | 0.29 | 4.19 | 0.58 | 3.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.81% | 10.97% | 10.46% | 12.39% |
| Free Cash Flow Growth | -90.04% | 208.70% | -75.31% | 309.31% |
| Safety | ||||
| Net Debt / EBITDA | -10.92 | -13.59 | -4.55 | -5.87 |
| Interest Coverage | 0.00 | 248.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.68 | 0.73 | 0.88 | 0.53 |
| Cash Conversion Cycle | 137.98 | 130.49 | 122.37 | 168.26 |